Hydrogel-based Technologies in Liquid Biopsy for the Detection of Circulating Clinical Markers: Challenges and Prospects

Overview

Journal Anal Bioanal Chem

Specialty Chemistry

Date 2023 Nov 14

PMID 37963993

Authors

Young Jun Kim

Junhong Min

Affiliations

Soon will be listed here.

Abstract

Liquid biopsy, which promises noninvasive detection of tumor-derived material, has recently been highlighted because of its potential to lead us to an era of precision medicine. However, its development has encountered challenges owing to the extremely low frequency and low purity of circulating tumor markers, such as circulating tumor cells (CTCs), circulating exosomes, and circulating tumor nucleic acids (ctNAs). Much effort has been made to overcome this limitation over the last decade, and an increasing number of studies have shown interest in the special characteristics of hydrogels. This hydrophilic and biocompatible polymeric network, which absorbs a large amount of water, can aid in the isolation, protection, and analysis of these low-abundance and short-lived circulating biomarkers. The role of hydrogels in liquid biopsy is extensive and ranges from enrichment to encapsulation. This review provides an overview of hydrogel-based technologies to pave the way in liquid biopsy.

Citing Articles

Polysaccharide Hydrogel-Assisted Biosensing Platforms for Point-of-Care Use.

Kim S, Kim Y, Lee T Biosensors (Basel). 2025; 15(1).

PMID: 39852065 PMC: 11763626. DOI: 10.3390/bios15010013.

Optical nanomaterial-based detection of biomarkers in liquid biopsy.

Kim Y, Rho W, Park S, Jun B J Hematol Oncol. 2024; 17(1):10.

PMID: 38486294 PMC: 10938695. DOI: 10.1186/s13045-024-01531-y.

References

Speicher M, Pantel K . Tumor signatures in the blood. Nat Biotechnol. 2014; 32(5):441-3. DOI: 10.1038/nbt.2897. View

Arechederra M, Avila M, Berasain C . Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. Adv Lab Med. 2023; 1(3):20200009. PMC: 10197281. DOI: 10.1515/almed-2020-0009. View

Gold B, Cankovic M, Furtado L, Meier F, Gocke C . Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015; 17(3):209-24. PMC: 4411248. DOI: 10.1016/j.jmoldx.2015.02.001. View

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

Longo D . Tumor heterogeneity and personalized medicine. N Engl J Med. 2012; 366(10):956-7. DOI: 10.1056/NEJMe1200656. View

Ignatiadis M, Sledge G, Jeffrey S . Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021; 18(5):297-312. DOI: 10.1038/s41571-020-00457-x. View

Crosbie P, Shah R, Krysiak P, Zhou C, Morris K, Tugwood J . Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. J Thorac Oncol. 2016; 11(10):1793-7. PMC: 5063509. DOI: 10.1016/j.jtho.2016.06.017. View

Madsen A, Hojbjerg J, Sorensen B, Winther-Larsen A . Day-to-day and within-day biological variation of cell-free DNA. EBioMedicine. 2019; 49:284-290. PMC: 6945267. DOI: 10.1016/j.ebiom.2019.10.008. View

Bach S, Wever B, van de Wiel M, Veltman J, Hashemi S, Kazemier G . Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients. Epigenetics. 2021; 17(10):1057-1069. PMC: 9542718. DOI: 10.1080/15592294.2021.1982511. View

10.

Zhe X, Cher M, Bonfil R . Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res. 2011; 1(6):740-51. PMC: 3195935. View

11.

Jeong Nam S, Yeo H, Chang H, Kim B, Hong E, Park J . A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer. Cancer Res Treat. 2016; 48(4):1229-1242. PMC: 5080828. DOI: 10.4143/crt.2015.500. View

12.

De Rubis G, Rajeev Krishnan S, Bebawy M . Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol Sci. 2019; 40(3):172-186. DOI: 10.1016/j.tips.2019.01.006. View

13.

Plaks V, Koopman C, Werb Z . Cancer. Circulating tumor cells. Science. 2013; 341(6151):1186-8. PMC: 3842225. DOI: 10.1126/science.1235226. View

14.

Swennenhuis J, van Dalum G, Zeune L, Terstappen L . Improving the CellSearch® system. Expert Rev Mol Diagn. 2016; 16(12):1291-1305. DOI: 10.1080/14737159.2016.1255144. View

15.

Meng S, Tripathy D, Frenkel E, Shete S, Naftalis E, Huth J . Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004; 10(24):8152-62. DOI: 10.1158/1078-0432.CCR-04-1110. View

16.

Nagrath S, Sequist L, Maheswaran S, Bell D, Irimia D, Ulkus L . Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450(7173):1235-9. PMC: 3090667. DOI: 10.1038/nature06385. View

17.

Stott S, Hsu C, Tsukrov D, Yu M, Miyamoto D, Waltman B . Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010; 107(43):18392-7. PMC: 2972993. DOI: 10.1073/pnas.1012539107. View

18.

Kim Y, Kang Y, Cho Y . Poly(ethylene glycol)-Modified Tapered-Slit Membrane Filter for Efficient Release of Captured Viable Circulating Tumor Cells. Anal Chem. 2016; 88(16):7938-45. DOI: 10.1021/acs.analchem.5b04927. View

19.

Talasaz A, Powell A, Huber D, Berbee J, Roh K, Yu W . Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A. 2009; 106(10):3970-5. PMC: 2645911. DOI: 10.1073/pnas.0813188106. View

20.

Krebs M, Metcalf R, Carter L, Brady G, Blackhall F, Dive C . Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014; 11(3):129-44. DOI: 10.1038/nrclinonc.2013.253. View